Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Tamoxifen is nominally called an 'anti-estrogen' although it has some estrogen-agonist activities and tends to increase plasma endogenous estrogen levels. Several studies have confirmed that it decreases plasma total cholesterol and LDL-cholesterol and a review of mortality in patients taking tamoxifen as adjuvant therapy for breast cancer indicates a decreased number of vascular deaths in women on tamoxifen compared to those not on this agent.
DESIGN NARRATIVE:
Subjects were randomized to receive 10 mg of tamoxifen two times a day or to placebo. The primary endpoint was prev...
Gender
FEMALE
Eligibility criteria
- • Women over the age of 35 with a 5-year predicted breast cancer risk of at least 1.66 percent or a history of lobular breast carcinoma in situ, life expectancy of 10 years or more, breast examination and mammogram without evidence of cancer, no hormonal therapy within three months prior to randomization, and no history of deep venous thrombosis or pulmonary embolism. .
About Nsabp Foundation Inc
The NSABP Foundation Inc. is a leading nonprofit organization dedicated to advancing research in breast and colorectal cancer through innovative clinical trials and collaborative studies. Established from the National Surgical Adjuvant Breast and Bowel Project, the foundation focuses on improving patient outcomes by evaluating new treatment modalities, enhancing early detection strategies, and promoting evidence-based practices in oncology. With a commitment to scientific excellence and patient-centric approaches, NSABP Foundation Inc. plays a pivotal role in shaping the future of cancer care and fostering partnerships among researchers, healthcare professionals, and patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials